Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Investors in biotechs are a greedy bunch

<< Previous

Bullboard Posts

Next >>

Comment by Bucknelly21on Nov 09, 2021 6:13pm

113 Views

Post# 34107224

RE:Investors in biotechs are a greedy bunch

Not sure what your timeline for legacy drugs to be meaningful but it will be years in my opinion

palinc2000 wrote: and far from being risk adversed,,,Paul has or had an excellent reputation prior to joinung THTX
Paul s comment as being EXTREMELY EXCITED about Phase 1 should have been a SP booster .....
Yet Nothing changed after Pauls comments...No upgrades on oncology no new oncology analysts
I cant believe that cancer experts hired by investment firms have not been shown THTX material.

Paul will be judged harshly if Pase 1 turns out to be a nothingburgerI.had high hope after his comment but now hope has diminished and very little expectations,,However I am still high on Nash and revenues of legacy drugs